AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More
ASTRAZENECA PHARMA | PFIZER | ASTRAZENECA PHARMA/ PFIZER |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 129.2 | 50.1 | 257.6% | View Chart |
P/BV | x | 39.5 | 8.3 | 474.9% | View Chart |
Dividend Yield | % | 0.0 | 0.4 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
PFIZER Mar-19 |
ASTRAZENECA PHARMA/ PFIZER |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 3,840 | 33.3% | |
Low | Rs | 883 | 2,080 | 42.4% | |
Sales per share (Unadj.) | Rs | 228.4 | 455.0 | 50.2% | |
Earnings per share (Unadj.) | Rs | 10.4 | 93.8 | 11.1% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 109.4 | 14.9% | |
Dividends per share (Unadj.) | Rs | 0 | 22.50 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.8 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 658.2 | 15.0% | |
Shares outstanding (eoy) | m | 25.00 | 45.75 | 54.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.7 | 6.5 | 72.7% | |
Avg P/E ratio | x | 104.2 | 31.6 | 330.2% | |
P/CF ratio (eoy) | x | 66.4 | 27.1 | 245.5% | |
Price / Book Value ratio | x | 10.9 | 4.5 | 243.2% | |
Dividend payout | % | 0 | 24.0 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 135,420 | 19.9% | |
No. of employees | `000 | 1.4 | 2.6 | 51.5% | |
Total wages/salary | Rs m | 1,535 | 3,238 | 47.4% | |
Avg. sales/employee | Rs Th | 4,210.9 | 7,911.4 | 53.2% | |
Avg. wages/employee | Rs Th | 1,132.2 | 1,230.9 | 92.0% | |
Avg. net profit/employee | Rs Th | 191.1 | 1,630.7 | 11.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 20,815 | 27.4% | |
Other income | Rs m | 123 | 1,674 | 7.3% | |
Total revenues | Rs m | 5,833 | 22,489 | 25.9% | |
Gross profit | Rs m | 463 | 5,712 | 8.1% | |
Depreciation | Rs m | 147 | 714 | 20.6% | |
Interest | Rs m | 0 | 73 | 0.0% | |
Profit before tax | Rs m | 438 | 6,599 | 6.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 2,309 | 7.7% | |
Profit after tax | Rs m | 259 | 4,291 | 6.0% | |
Gross profit margin | % | 8.1 | 27.4 | 29.5% | |
Effective tax rate | % | 40.8 | 35.0 | 116.8% | |
Net profit margin | % | 4.5 | 20.6 | 22.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 27,167 | 11.8% | |
Current liabilities | Rs m | 2,070 | 8,917 | 23.2% | |
Net working cap to sales | % | 20.0 | 87.7 | 22.8% | |
Current ratio | x | 1.6 | 3.0 | 50.9% | |
Inventory Days | Days | 72 | 68 | 106.7% | |
Debtors Days | Days | 35 | 30 | 116.0% | |
Net fixed assets | Rs m | 790 | 8,862 | 8.9% | |
Share capital | Rs m | 50 | 458 | 10.9% | |
"Free" reserves | Rs m | 2,419 | 29,656 | 8.2% | |
Net worth | Rs m | 2,469 | 30,113 | 8.2% | |
Long term debt | Rs m | 0 | 25 | 0.0% | |
Total assets | Rs m | 4,605 | 39,400 | 11.7% | |
Interest coverage | x | NM | 91.5 | - | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 1.2 | 0.5 | 234.7% | |
Return on assets | % | 5.6 | 11.1 | 50.8% | |
Return on equity | % | 10.5 | 14.2 | 73.6% | |
Return on capital | % | 17.7 | 22.1 | 80.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 428 | 69.9% | |
Fx outflow | Rs m | 2,015 | 786 | 256.2% | |
Net fx | Rs m | -1,715 | -358 | 479.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 978 | 9.0% | |
From Investments | Rs m | -94 | 351 | -26.7% | |
From Financial Activity | Rs m | NA | -1,099 | 0.0% | |
Net Cashflow | Rs m | -6 | 231 | -2.5% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 75.0 | 63.9 | 117.4% | |
Indian inst/Mut Fund | % | 0.3 | 7.5 | 4.0% | |
FIIs | % | 15.7 | 4.9 | 320.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 23.7 | 38.4% | |
Shareholders | 12,856 | 85,207 | 15.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: AUROBINDO PHARMA SHASUN PHARMA SANOFI INDIA J.B.CHEMICALS ORCHID PHARMA
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video I tell you the three Nifty ETFs I think are the best.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More